PCM
REGN icon

Prelude Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Prelude Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,000
Closed -$966K – 1772
2020
Q4 		$966K Hold
2,000
– – 0.02% 487
2020
Q3 		$1.12M Hold
2,000
– – 0.05% 254
2020
Q2 		$1.25M Buy
+2,000
New +$1.14M 0.07% 264
2015
Q3 		– Sell
-700
Closed -$357K – 1729
2015
Q2 		$357K Hold
700
– – 0.05% 399
2015
Q1 		$316K Buy
+700
New +$297K 0.04% 486

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Prelude Capital Management's REGN Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 744 shares worth $464K. The stake represents 0.03% of the portfolio and ranks #560 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in REGN as recently as Q4 2025.

Prelude Capital Management first reported a position in REGN in Q2 2013 and has held it in 35 quarters since. The position peaked at $1.17M in Q2 2013. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Prelude Capital Management held 744 shares of Regeneron Pharmaceuticals worth $464K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Prelude Capital Management position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Prelude Capital Management's portfolio in Q2 2026, its #560 holding.
  • Prelude Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
  • Prelude Capital Management's Regeneron Pharmaceuticals position peaked at $1.17M in Q2 2013.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.